MX9806191A - Composicion que comprende inhibidor de interleucina 1 y polimero de liberacion controlada. - Google Patents
Composicion que comprende inhibidor de interleucina 1 y polimero de liberacion controlada.Info
- Publication number
- MX9806191A MX9806191A MX9806191A MX9806191A MX9806191A MX 9806191 A MX9806191 A MX 9806191A MX 9806191 A MX9806191 A MX 9806191A MX 9806191 A MX9806191 A MX 9806191A MX 9806191 A MX9806191 A MX 9806191A
- Authority
- MX
- Mexico
- Prior art keywords
- controlled release
- composition
- release polymer
- interleukin
- inhibitor
- Prior art date
Links
- 102000000589 Interleukin-1 Human genes 0.000 title abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 abstract 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
Abstract
Se describe una composicion farmacéutica que comprende (a) una cantidad efectiva de un polímero de liberacion controlada y (b) una cantidad efectiva de IL-1ra. La composicion muestra un efecto terapéutico sobre la inflamacion, y es util para el tratamiento de enfermedades inflamatorias mediadas por IL-1, particularmente enfermedades de las articulaciones.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1141996P | 1996-02-09 | 1996-02-09 | |
US3278996P | 1996-12-06 | 1996-12-06 | |
US3624197P | 1997-01-23 | 1997-01-23 | |
US08/798,414 US6096728A (en) | 1996-02-09 | 1997-02-07 | Composition and method for treating inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9806191A true MX9806191A (es) | 1998-10-31 |
Family
ID=27486083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9806191A MX9806191A (es) | 1996-02-09 | 1998-07-31 | Composicion que comprende inhibidor de interleucina 1 y polimero de liberacion controlada. |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0904112B1 (es) |
JP (2) | JP4344404B2 (es) |
KR (1) | KR20040010739A (es) |
CN (1) | CN1215340A (es) |
AT (1) | ATE448797T1 (es) |
AU (1) | AU724960C (es) |
BR (1) | BR9707325A (es) |
CA (2) | CA2539273C (es) |
CZ (1) | CZ299025B6 (es) |
DE (1) | DE69739656D1 (es) |
EA (2) | EA001792B1 (es) |
ES (1) | ES2334726T3 (es) |
HU (1) | HU230160B1 (es) |
IL (1) | IL125552A0 (es) |
MX (1) | MX9806191A (es) |
NO (1) | NO983543L (es) |
NZ (2) | NZ503548A (es) |
SK (1) | SK288144B6 (es) |
WO (1) | WO1997028828A1 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2312179T3 (es) | 1996-12-06 | 2009-02-16 | Amgen Inc. | Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1. |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
AU773891C (en) | 1998-10-23 | 2005-02-17 | Kirin-Amgen Inc. | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
AT406054B (de) * | 1998-11-04 | 2000-02-25 | Andreas Bernkop-Schnuerch | Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung |
DE60024636T2 (de) * | 1999-06-21 | 2006-08-17 | Santen Pharmaceutical Co., Ltd | Arzneimittel für die rheumatoide arthritis |
CA2378880C (en) * | 1999-07-21 | 2010-02-23 | Omeros Medical Systems, Inc. | Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
WO2001083525A2 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
US7324635B2 (en) | 2000-05-04 | 2008-01-29 | Telemaze Llc | Branch calling and caller ID based call routing telephone features |
EP2241328A1 (en) * | 2000-05-12 | 2010-10-20 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
KR20040023630A (ko) | 2001-06-26 | 2004-03-18 | 아브게닉스, 인크. | Opgl에 결합하는 항체 |
US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
WO2003061626A1 (en) * | 2002-01-18 | 2003-07-31 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
US7026326B2 (en) | 2002-05-21 | 2006-04-11 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
TWI347951B (en) | 2002-09-06 | 2011-09-01 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US7429378B2 (en) | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
US10765747B2 (en) * | 2004-04-02 | 2020-09-08 | Swedish Orphan Biovitrum Ab (Publ) | Methods of reducing aggregation of IL-1ra |
EP2664334B1 (en) * | 2004-12-30 | 2015-03-04 | Genzyme Corporation | Regimens for intra-articular viscosupplementation |
CN101500606B (zh) * | 2005-06-24 | 2013-12-04 | 杜克大学 | 基于热反应生物聚合物的直接药物送递*** |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
GB0708376D0 (en) | 2007-05-01 | 2007-06-06 | Alligator Bioscience Ab | Novel polypeptides and uses thereof |
CN101918018B (zh) | 2007-11-14 | 2012-12-05 | 再生医药有限公司 | 使用白介素-1受体拮抗剂作为骨髓保护剂的方法 |
US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
EP2620139B1 (en) | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1 receptor antagonist rich solutions |
KR200451958Y1 (ko) * | 2008-10-09 | 2011-01-21 | (주)에이치시티 | 모바일기기용 카드형 안테나장치 |
AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
CN101690801B (zh) | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
DE202009017772U1 (de) | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
KR20130130825A (ko) * | 2011-02-08 | 2013-12-02 | 애브비 인코포레이티드 | 골관절염 및 통증의 치료 방법 |
WO2012108828A1 (en) | 2011-02-11 | 2012-08-16 | Swedish Orphan Biovitrum Ab (Publ) | Citrate free pharmaceutical compositions comprising anakinra |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
WO2013030348A1 (en) | 2011-09-02 | 2013-03-07 | Novozymes Biopharma Dk A/S | Oral formulations containing hyaluronic acid for sustained drug release |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
AU2014333953C1 (en) * | 2013-10-08 | 2020-06-25 | Ascendis Pharma A/S | Hydrogel-linked IL-1ra prodrug |
WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
CZ309295B6 (cs) * | 2015-03-09 | 2022-08-10 | Contipro A.S. | Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití |
WO2018022982A1 (en) | 2016-07-29 | 2018-02-01 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
SG10202107829YA (en) | 2017-03-22 | 2021-08-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
JP7241782B2 (ja) * | 2018-06-22 | 2023-03-17 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 顎関節変性疾患の治療用の持続放出性組成物およびその方法 |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
WO2020112853A1 (en) * | 2018-11-28 | 2020-06-04 | Genascence Corporation | Methods and compositions for treating osteoarthritis |
CN114206366A (zh) * | 2019-08-08 | 2022-03-18 | 艾维登斯医疗公司 | 基于微球的可注射塞来昔布制剂 |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Il‐2レセプター特異的キメラ抗体 |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
DK0393438T3 (da) | 1989-04-21 | 2005-05-30 | Amgen Inc | TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
AU649245B2 (en) * | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
WO1991017184A1 (en) | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
NO940913L (no) * | 1993-03-26 | 1994-09-27 | Bristol Myers Squibb Co | Preparater for kontrollert frigivelse av biologisk aktiv TGF- |
JPH06321803A (ja) * | 1993-05-17 | 1994-11-22 | Kirin Brewery Co Ltd | 水溶性ペプチドホルモンの徐放性製剤 |
US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
WO1995010298A1 (en) * | 1993-10-12 | 1995-04-20 | Mary Lake Polan | Method of contraception |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
JPH10503179A (ja) | 1994-06-24 | 1998-03-24 | イミュネックス・コーポレーション | 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法 |
IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
-
1997
- 1997-02-10 DE DE69739656T patent/DE69739656D1/de not_active Expired - Lifetime
- 1997-02-10 WO PCT/US1997/002131 patent/WO1997028828A1/en not_active Application Discontinuation
- 1997-02-10 AT AT97906551T patent/ATE448797T1/de not_active IP Right Cessation
- 1997-02-10 AU AU21213/97A patent/AU724960C/en not_active Expired
- 1997-02-10 CN CN97193632A patent/CN1215340A/zh active Pending
- 1997-02-10 NZ NZ503548A patent/NZ503548A/en unknown
- 1997-02-10 CZ CZ0237398A patent/CZ299025B6/cs not_active IP Right Cessation
- 1997-02-10 EA EA199800694A patent/EA001792B1/ru not_active IP Right Cessation
- 1997-02-10 JP JP52874197A patent/JP4344404B2/ja not_active Expired - Lifetime
- 1997-02-10 HU HU9902612A patent/HU230160B1/hu unknown
- 1997-02-10 ES ES97906551T patent/ES2334726T3/es not_active Expired - Lifetime
- 1997-02-10 CA CA2539273A patent/CA2539273C/en not_active Expired - Lifetime
- 1997-02-10 EA EA200000825A patent/EA200000825A1/ru unknown
- 1997-02-10 EP EP97906551A patent/EP0904112B1/en not_active Expired - Lifetime
- 1997-02-10 BR BR9707325A patent/BR9707325A/pt not_active Application Discontinuation
- 1997-02-10 NZ NZ331163A patent/NZ331163A/xx unknown
- 1997-02-10 CA CA002244664A patent/CA2244664C/en not_active Expired - Lifetime
- 1997-02-10 IL IL12555297A patent/IL125552A0/xx unknown
- 1997-02-10 KR KR10-2003-7016565A patent/KR20040010739A/ko not_active Application Discontinuation
- 1997-02-10 SK SK1036-98A patent/SK288144B6/sk not_active IP Right Cessation
-
1998
- 1998-07-31 NO NO983543A patent/NO983543L/no not_active Application Discontinuation
- 1998-07-31 MX MX9806191A patent/MX9806191A/es active IP Right Grant
-
2007
- 2007-05-22 JP JP2007136048A patent/JP2007211027A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NO983543L (no) | 1998-10-08 |
EA001792B1 (ru) | 2001-08-27 |
HUP9902612A2 (hu) | 1999-11-29 |
CA2539273C (en) | 2014-02-04 |
CA2539273A1 (en) | 1997-08-14 |
DE69739656D1 (de) | 2009-12-31 |
JP4344404B2 (ja) | 2009-10-14 |
KR20040010739A (ko) | 2004-01-31 |
SK103698A3 (en) | 2001-01-18 |
CZ299025B6 (cs) | 2008-04-02 |
CZ237398A3 (cs) | 1999-09-15 |
EA199800694A1 (ru) | 1999-02-25 |
BR9707325A (pt) | 1999-04-13 |
WO1997028828A1 (en) | 1997-08-14 |
CA2244664A1 (en) | 1997-08-14 |
NO983543D0 (no) | 1998-07-31 |
CN1215340A (zh) | 1999-04-28 |
IL125552A0 (en) | 1999-03-12 |
ES2334726T3 (es) | 2010-03-15 |
ATE448797T1 (de) | 2009-12-15 |
EP0904112A1 (en) | 1999-03-31 |
HU230160B1 (hu) | 2015-09-28 |
JP2007211027A (ja) | 2007-08-23 |
AU724960C (en) | 2002-08-15 |
NZ331163A (en) | 2000-07-28 |
CA2244664C (en) | 2008-06-03 |
EA200000825A1 (ru) | 2001-02-26 |
AU724960B2 (en) | 2000-10-05 |
NZ503548A (en) | 2001-09-28 |
AU2121397A (en) | 1997-08-28 |
HUP9902612A3 (en) | 2001-11-28 |
JP2001500472A (ja) | 2001-01-16 |
SK288144B6 (sk) | 2013-12-02 |
EP0904112B1 (en) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL125552A0 (en) | Composition comprising interleukin-1 inhibitor and controlled release polymer | |
AU3201095A (en) | Substituted thiazoles for the treatment of inflammation | |
CA2031880A1 (en) | Combined anti-inflammatory agent | |
EP1092433A3 (en) | Compositions and methods for treating or preventing inflammatory diseases | |
FI971969A0 (fi) | Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä | |
WO1999062510A3 (en) | Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases | |
AU7484798A (en) | Methods for treating inflammation, inflammatory diseases, arthritis and strok e using padprt inhibitors | |
DE59808545D1 (de) | Mittel zur hormonalen kontrazeption | |
EE04416B1 (et) | a1L- agonistide kasutamine uriiniinkontinentsuse raviks | |
AU2027695A (en) | Pharmaceutical composition for treating stoma-peripheral inflammation diseases | |
DE59700356D1 (en) | Kombinationspräparat, enthaltend 5-methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid und n-(4-trifluormethylphenyl)-2-cyan-3-hydroxycrotonsäureamid | |
EP1776954A3 (en) | The use of inhibitors of the renin-angiotensin system for the treatment of stroke | |
SE9604751D0 (sv) | New therapy | |
NO20016068D0 (no) | Anvendelse av oksypurin-nukleosider for fremstilling av et farmasöytisk preparat for redusering av inflammasjon i et dyr | |
AU4133997A (en) | Pharmaceutical composition for the treatment of syndrome x of reaven | |
AU3528195A (en) | Pharmaceutical control of inflammation | |
AU1277397A (en) | Steroid nitrite ester derivatives useful as anti-inflammatory drugs | |
AU1576999A (en) | Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation | |
AU7042796A (en) | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases | |
ID18382A (id) | Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase | |
MY129782A (en) | Novel medical use | |
AU4726797A (en) | Prophylactic/remedial agent | |
IL120909A0 (en) | Compositions and means for the treatment of burns and other cutaneous traumas | |
EP0826374A3 (en) | Pharmaceutical composition for prophylaxis and/or treatment of apoptosis-related diseases | |
AU2001292818A1 (en) | Use of transcription factors for treating inflammation and other diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |